Biohaven Ltd. (BHVN)
| Market Cap | 2.40B +61.6% |
| Revenue (ttm) | n/a |
| Net Income | -647.68M |
| EPS | -5.44 |
| Shares Out | 150.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,530,657 |
| Open | 15.89 |
| Previous Close | 15.76 |
| Day's Range | 15.60 - 16.51 |
| 52-Week Range | 7.48 - 18.57 |
| Beta | 3.30 |
| Analysts | Buy |
| Price Target | 22.00 (+37.85%) |
| Earnings Date | Jul 30, 2026 |
About BHVN
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for BHVN stock is "Buy." The 12-month stock price target is $22.0, which is an increase of 37.85% from the latest price.
News
Biohaven announces completion of enrollment in RISE3 trial
Biohaven (BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled studies evaluating its selective Kv7.2/7.3 channel activator, opakalim...
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026 Emerging opakalim focal epilepsy and idiopathic generalized epilepsy...
Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease
Biohaven (BHVN) announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves’ disease. BHV-1300 is the first MoDE extracellular protein degrader, a novel small…
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a new class of precision immunology medicines that eliminate the disease-driving antibodies at the root ...
Biohaven downgraded to Underperform from Neutral at BofA
BofA downgraded Biohaven (BHVN) to Underperform from Neutral with a price target of $11, down from $12, to reflect a “bearish view” on the risk-reward into the next major near-term…
Biohaven price target raised to $20 from $15 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Biohaven (BHVN) to $20 from $15 and keeps a Buy rating on the shares. The firm says the company’s troriluzole in spinocerebellar…
Biohaven initiates first-in-human dosing for BHV-8100
Biohaven (BHVN) announced the initiation of first-in-human dosing for BHV-8100, its oral, brain-penetrant pyruvate kinase M2 isoform modulator. Dr. Bruce Car, Chief Scientific Officer of Biohaven, sta...
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders Fir...
Biohaven’s candidates in Graves’ Disease and IgA nephropathy shows efficacy
Biohaven (BHVN) reported “compelling” results regarding its proprietary extracellular MoDE – BHV-1300 – and TRAP – BHV-1400 – degrader platform. Key highlights from the Phase 1b Graves’ Disease patien...
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
BHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-IgG1) in patients with Graves' hyperthyroidism receiving 1000 mg SC weekly, with mean reductions in TS...
Biohaven reports data from selective Kv7.2/7.3 channel activator program
Biohaven (BHVN) reported new data from its selective Kv7.2/7.3 channel activator program, currently in Phase 2/3 studies for the treatment of focal epilepsy, and will present additional updates at its...
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a generalized tonic-clonic seizure was 141 days in the opakali...
Biohaven price target lowered to $18 from $21 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biohaven (BHVN) to $18 from $21 and keeps an Overweight rating on the shares.
Biohaven price target lowered to $22 from $23 at RBC Capital
RBC Capital lowered the firm’s price target on Biohaven (BHVN) to $22 from $23 and keeps an Outperform rating on the shares. The company’s Q1 results indicate that programs are…
Biohaven price target lowered to $12 from $14 at BofA
BofA lowered the firm’s price target on Biohaven (BHVN) to $12 from $14 and keeps a Neutral rating on the shares. The firm views the company’s Q1 report as largely…
Biohaven files automatic mixed securities shelf
16:27 EDT Biohaven (BHVN) files automatic mixed securities shelf
Biohaven reports Q1 adjusted EPS (69c), consensus (76c)
Reports Q1 R&D expenses, including non-cash share-based compensation costs, $103.8M, compared to $187.6M last year. Vlad Coric, Chairman and CEO of Biohaven (BHVN), commented, “We are planning for a t...
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026. Advancement of high-value, late-stage priority programs: Piv...
Biohaven Quarterly report: Q1 2026
Biohaven has published its Q1 2026 quarterly earnings report on May 4, 2026.
Biohaven Earnings release: Q1 2026
Biohaven released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhi...
Biohaven Proxy statement: Proxy Filing
Biohaven filed a proxy statement on March 13, 2026, providing details for shareholder voting and corporate governance matters.
Biohaven Proxy statement: Proxy Filing
Biohaven filed a proxy statement on March 13, 2026, providing details for shareholder voting and corporate governance matters.